Background: The Medical Admission Risk System (MARS) uses 11 physiological and laboratory data and had promising results in its derivation study for predicting 5-and 7-day mortality. Aim: To perform an external independent validation of the MARS score. Design: An unplanned secondary cohort study. Results: Patients of 5858 were included in the study. Patients of 2923 (49.9%) were women with a median age of 65 years (15-107). The MARS score had an area under the receiving operator characteristic curve of 0.858 (95% CI: 0.831-0.884) for 5-day mortality and 0.844 (0.818-0.870) for 7 day mortality with poor calibration for both outcomes. Conclusion: The MARS score had excellent discriminatory power but poor calibration in predicting both 5-and 7-day mortality. The development of accurate combination physiological/laboratory data risk scores has the potential to improve the recognition of at risk patients.
Introduction
Predicting outcomes in acutely unwell patients is challenging but essential in order to facilitate safe emergency care. Patients at risk of rapid deterioration and critical illness often have preceding changes in their physiological parameters. [1] [2] [3] Early warning scores, such as National Early Warning Score and Vitalpac EWS, are routinely used in practice to help identify patients at risk of adverse outcomes and potentially requiring Critical Care admission. [4] [5] [6] Early warning scores perform variably in different acute medical presentations and some of the physiological parameters utilized in the scores have poor predictive value of acute deterioration. 7, 8 The addition of laboratory data, such as d-dimer and lactate, to early warning scores has been shown to improve their performance. 9, 10 The development of more accurate combination physiological/laboratory data risk scores has the potential to improve the recognition of at risk patients. The Medical Admission Risk System (MARS) is a risk prediction score consisting of vital signs and laboratory parameters that can be used to predict 5-and 7-day-mortality. It uses 11 physiological and laboratory data and had promising results in its derivation study. 11 We performed an external independent validation at a regional teaching hospital in Denmark. The aim of this study was to validate the MARS score using both 5-to 7-day in-hospital mortality as the primary endpoint, In addition, stratified analyses regarding ICD-10 diagnoses were performed, for early recognition of deterioration in a range of disease groups.
Materials and methods
We performed an unplanned, secondary cohort study with data collected prospectively but analysed retrospectively. Upon arrival, a nurse recorded the patients' vital signs and basic demographic information using a structured protocol, as part of the daily clinical practice. This data is manually entered into a database. Laboratory data required for the MARS are taken as part of routine clinical care. The Charlson comorbidity score were extracted from the National Patient Register. 12 We used the original MARS score without modification (see table 1 ) and calculated the discriminatory power as the area under the receiving operator characteristic curve (AUROC) and calibration using Hosmer-Lemeshow goodness-of-fit test. Sub-analyses were performed. Stata 13.1 was used for analyses.
Results
Patients of 5858 were admitted during the study periods. Full sets of data were available for 3904 (66.6%) patients and 5012 (85.6%) for the sub-analysis. Patients of 2923 (49.9%) were women with a median age of 65 years (15-107). The median length of stay was 2 days (0-389). Patients of 2117 (36.1%) had a Charlson co-morbidity score (CCS) of 0, 1131 (19.3%) had CCS ¼ 1851 (14.5%) CCS ¼2 and 1759 (30%) patients had a CCS of 3 or more. Of the 5858 admitted patients, 109 (1.9%) patients died within 5 days and 133 (2.3%) died within 7 days.
Of the 3904 patients with full data sets included in the analysis 67 (1.7%) patients had 5-day mortality and 84 (2.2%) patients a 7-day mortality. There was no significant difference between all admitted patients and those included for analysis, in 5-day mortality (P ¼ 0.35) or 7-day mortality (P ¼ 0.54). Patients included in the analyses were older than all admitted patients, with a median age of 62.6 vs. 60.4 (P < 0.01) and had a higher CCS (P ¼ 0.001). The main causes of 5-day mortality were infective (24 patients) and cardiorespiratory (20 patients).
The MARS score had an AUROC of 0.858 (95% CI: 0.831-0.884) for 5-day mortality. Calibration was poor, X 2 ¼ 383.09, with 10 degrees of freedom (P < 0.001). AUROC was also calculated regarding ICD-10 diagnostic groups (Figure 1 ). For 7-day mortality, the AUROC was 0.844 (0.818-0.870). Calibration for 7 day mortality was also poor (X 2 ¼ 5830.20, also with 10 degrees of freedom P < 0.001). AUROC for 7-day mortality based on ICD-10 diagnostic groups are shown in Figure 2 .
A sub-group analysis with only age and the five laboratory data included in the MARS score was performed. For 5-day mortality the AUROC was 0.844 (0.820-0.867) with poor calibration (X 2 ¼ 642.02, 10 degrees of freedom and P < 0.001; Figure 3 ).
Discussion
In this validation study of 5858 adult Danish medical patients, the MARS score had excellent discriminatory power but poor calibration in predicting both 5-and 7-day mortality. In our cohort, the 5-day mortality rate was 1.7% compared to 6.1% in the initial derivation study cohort. This may reflect differences in the Irish and Danish health care systems and varying casemixes. Less patients were included in the main analysis (3904 of 5858) than in the sub-analysis (5012 of 5858). The reasons could be fewer required parameters in the sub-analysis, the variables included are different and thus there is a different number that must be excluded. The MARS score has excellent discriminatory power in a range of disease groups. This strength means it not only has utility in an unselected cohort but can help facilitate early recognition of deterioration in disease groups where decisions regarding escalation of care are more challenging.
The development of more accurate combination physiological/laboratory data risk scores has the potential to improve the recognition of at risk patients. These will need to be increasingly disease-specific so that they are responsive to advances in treatment outcomes whilst maintaining their performance in an unselected general emergency cohort.
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